Groundbreaking pediatric non-verbal disorder treatment QBM-001 presented to over 30,000 drug discovery professionals through print edition of DDN News
New York, New York--(Newsfile Corp. - February 26, 2019) - Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, today announced that in the February issue of DDNews, journalists conducted an interview with Q BioMed CEO Dennis Corin, focused on the mechanism of action, development path, and market opportunities of QBM-001 which is being developed to help treat rare pediatric non-verbal autism spectrum disorder. The article is available at the following link on page 21 and 23: http://ddn-news.com/lib/sitefiles/pdf/Issues/DDNEWS_0219.pdf
Among the over 60,000 U.S. children who develop Autism Spectrum Disorders (ASD) every year, approximately 20,000 become non-verbal. The statistics are similar in Europe. Currently, there are no drugs available to treat this condition. As a result, the lifetime costs of assisted living and supplemental healthcare average $10 million per person and is currently estimated to cost the healthcare system over $200 billion a year. This is compounded by an additional $10 million during the lifespan of the person due to loss in productivity. There is no measure of the severe emotional strain for families when a child is non-verbal.
"QBM-001 is a combination therapy that is designed to reduce the levels of two molecules that are elevated in our target group by targeting multiple pathways. When these two molecules are elevated, they are known to induce neurodegeneration and inhibit speech," the article quoted Mr. Corin's description of the groundbreaking drug's mechanism of action.
DDNews' monthly print newspaper is circulated to more than 30,000 drug discovery research professionals throughout North America, where it delivers news that is specific to the pharma/biotech industries, always with a keen eye toward stories that affect the business of drug discovery.
DDNews is a respected monthly newspaper dedicated to the news of technology and business in the pharmaceutical and biotechnology industries. DDNews' website, www.ddn-news.com, is a fully integrated, online news portal housing in-depth content, industry resources, product literature, white papers and archived print issues. DDNews provides readers with links to additional editorial and product resources and web usage last year generated more than 4.6 million downloaded pages.
About Q BioMed Inc.
Q BioMed aims to accelerate the monetization of biomedical technologies through rapid innovation and collaborative partnerships with industry leading researchers. Q BioMed believes its assets in oncology, vascular disease, and rare orphan diseases address unmet medical needs and large markets. The Company's FDA approved, non-opioid drug Metastron, which relieves cancer bone pain, is expected to begin generating revenues in 2019. Metastron is also approved for sale in 21 other countries. In addition to treating pain, Metastron has shown evidence of treating the cancer itself and extending survival. Q BioMed plans to conduct Phase IV trials to support label extension and cancer survival benefit using Metastron.
For more information please visit www.qbiomed.com.
Forward Looking Statements:
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Q BioMed Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/43036